Ambulatory Transradial Percutaneous Coronary Intervention

Original title: Ambulatory Transradial Percutaneous Coronary Intervention: A Safe, Effective, and Cost-Saving Strategy. Reference: Philippe Le Corvoisier et al. Catheterization and Cardiovascular Interventions 81:15–23 (2013).

The number of PCI procedures has increased and for many interventional cardiology centers PC interventions entail significant resource consumption. Reducing post procedure hospital stay could reduce costs and optimize hospitalization resources. 

The safety of post PCI discharge the same day of procedure should be established before incorporation to daily practice. The aim of this prospective multicenter study was to determine the safety, cost and acceptance of patients undergoing ambulatory transradial PCI. The study took place in 3 high volume centers in France; it assessed 370 consecutive patients with stable angina or silent ischemia for coronary catheterization followed by PCI and same day discharge. From 370 patients, 220 were selected for 4-6 hr observation and discharge. 

Inclusion criteria were:

•+18 years

•Stable angina or silent ischemia

Exclusion criteria: 

•Clinical criteria

ACS, Symptomatic cardiac insufficiency and/or <35% ejection fraction, Severe chronic kidney disease (creatinine clearance

•Social criteria

Doubts on patient acceptance, Place of residence farther than 1 hour from hospital, Inadequate home care.

•PCI related criteria

Approach other than radial, Use of Glycoprotein IIb/IIIa inhibitors, < 3 post interventional TIMI flow , > 1 mm branch occlusion, Persistent chest pain, Hemodynamic instability during procedure, Ventricular arrhythmia during procedure, Procedure completed after 2 pm.

From the 220 patients, 213 (96.8%) were discharged after a 4-6 hr observation period. 4 patients remained hospitalized (1.8%) for cardiovascular reasons and 3 patients (1.4%) for non cardiovascular reasons. At one month follow up, one patient presented a non fatal infarction at day 4 for stent thrombosis and 3 patients were readmitted for atypical chest pain, without ECG changes or troponin elevation. 87% of patients were satisfied with ambulatory management and 96% were open to repeat the experience.

Conclusion 

Ambulatory PCI in stable patients is safe, feasible and well accepted by patients. It’s a promising strategy to lower costs and optimize healthcare resources.

Editorial Comment:

As an observational study, it fails to identify prediction factors; however, the study provides evidence in support of ambulatory PCI as daily practice: it included a significant number of patients with multiple vessels, bifurcations and recanalizations, due to the fact that all PCI procedures were ad hoc, which has external value and easily proves feasibility. Perhaps we could start including the least complex procedures and gain experience to include all procedures, as the present study did.

SOLACI.ORG

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...